Table 1.
Clinical characteristics of the cohort
| Total cases | 16 |
|---|---|
| Sex | |
| Male | 13 |
| Female | 3 |
| Age, median (range, year) | 62 (52–91) |
| <65 | 11 |
| ≥65 | 5 |
| Anatomic site | |
| Oropharynx | 4 |
| Oral cavity | 8 |
| Nasopharynx | 2 |
| Unknown primary | 1 |
| Nasal cavity | 1 |
| ECOG performance status | |
| 0 | 5 |
| 1 | 8 |
| 2 | 1 |
| 3 | 0 |
| 4 | 0 |
| Unknown | 2 |
| Treatment | |
| Pembrolizumab | 11 |
| Pembrolizumab + combinational therapy* | 5 |
| Tobacco use | |
| Never | 11 |
| Former | 5 |
| Alcohol consumption | |
| Current | 9 |
| Former | 2 |
| Never | 1 |
| Unknown | 4 |
| Stage | |
| Primary | 2 |
| Locoregional recurrent | 7 |
| Distant recurrence | 2 |
| Locoregional + distant recurrence | 5 |
| CPS | |
| <1 | 2 |
| 1–19 | 3 |
| ≥20 | 11 |
| Local therapy following ICB start | |
| Yes** | 3 |
| No | 13 |
| Number of prior lines of systemic therapy | |
| 0 | 13 |
| 1–2 | 2 |
| >2 | 1 |
| Number of infusions | |
| ≤5 | 10 |
| 10–20 | 4 |
| ≥21 | 2 |
| Viral status | |
| HPV | 4 |
| EBV | 1 |
| Negative | 11 |
*Pembrolizumab + chemotherapy: n = 4; Pembrolizumab + anti-CD47: n = 1; **Salvage surgery: n = 1; Salvage radiation n = 2.